The lack of progress concerning the concept of the hot flash experience in men is an indication of the need for exploration of this phenomenon. The hot flash experience in men is a problem that can no longer be ignored. The results of this literature review will provide a foundation for additional development of the concept and facilitate further inquiry into the phenomenon. The purpose of the article is to provide the current state of the science of hot flashes related to androgen ablation treatment in prostate cancer patients; sleep, sweating, cognitive impairment, and the implications on health-related quality of life. Due to the sparse literature on this concept in men, information is extrapolated from the literature on female breast cancer patients treated with hormones and on menopausal women.
American Cancer Society. (2005). Cancer facts and figures 2005. Retrieved February 12, 2005, from http://www.cancer.org/docroot/STT/STT-0.asp
2.
American Cancer Society. (2006). Cancer facts and figures 2006. Retrieved February 12, 2006, from http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
3.
Barsevick, A.M., Whitmer, K., Nail, L.M., Beck, S.L., & Dudley, W.N. (2006). Symptom cluster research: Conceptual, design, measurement, and analysis issues. Journal of Pain & Symptom Management, 31(1), 85-95.
4.
Beer, T.M., Bland, L.B., Bussiere, J.R., Neiss, M.B., Wersinger, E.M., Garzotto, M., et al. (2006). Testosterone loss and estradiol administration modify memory in men. Journal of Urology, 175, 130-135.
5.
Berger, A.M., Berry, D.L., Christopher, K.A., Greene, A.L., Maliski, S., Swenson, K.K., et al. (2005). Oncology Nursing Society year 2004 research priorities survey. Oncology Nursing Forum, 32, 281-290.
6.
Bressler, L.R., Murphy, C.M., Shevrin, D.H., & Warren, R.F. (1993). Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Annals of Pharmacotherapy, 27, 182-185.
7.
Cabot, A.T. (1896). The question of castration for enlarged prostate . Annals of Surgery, 24, 265.
8.
Calabro, F., & Sternberg, C.N. (2006). Current indications for chemotherapy in prostate cancer patients. European Urology , 51, 17-26.
9.
Carpenter, J.S. (2000). Hot flashes and their management in breast cancer . Seminars in Oncology Nursing, 16, 214-225.
10.
Carpenter, J.S. (2005a). Physiological monitor for assessing hot flashes . Clinical Nurse Specialist, 19(1), 8-10.
11.
Carpenter, J.S. (2005b). State of the science: Hot flashes and cancer. Part 1: Definition, scope, impact, physiology, and measurement. Oncology Nursing Forum, 32, 959-968.
12.
Carpenter, J.S., & Andrykowski, M.A. (1998). Psychometric evaluation of the Pittsburgh Sleep Quality Index. Journal of Psychosometric Research, 45(1), 5-13.
13.
Carpenter, J.S., Andrykowski, M.A., Cordova, M., Cunningham, L., Studts, J., McGrath, P., et al. (1998). Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life. Cancer, 82, 1682-1691.
14.
Carpenter, J.S., Andrykowski, M.A., Freedman, R.R., & Munn, R. (1999). Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause, 6(3), 209-215.
15.
Carpenter, J.S., Azzouz, F., Monahan, P.O., Storniolo, A.M., & Ridner, S.H. (2005). Is sternal skin conductance monitoring a valid measure of hot flash intensity or distress? Menopause, 12, 512-519.
16.
Carpenter, J.S., Elam, J., Ridner, S., Carney, P., Cherry, G., & Cucullu, H. (2004). Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncology Nursing Forum, 31, 5591-5598.
17.
Cervenakov, I., Kopecny, M., Jancar, M., Chovan, D., & Mal'a, M. (2000). `Hot flush,' an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. International Urology and Nephrology, 32(1), 77-79.
18.
Cherrier, M.M. (2005). Androgens and cognitive function. Journal of Endocrinology Investigation, 28(3 Suppl.), 65-75.
19.
Chodak, G. (2006). Prostate cancer: Epidemiology, screening, and biomarkers. Reviews in Urology, 8(Suppl. 2), S3-S8.
20.
Chu, K.C., Tarone, R.E., & Freeman, H.P. (2003). Trends in prostate cancer mortality among Black men and White men in the United States. Cancer, 97, 1507-1516.
21.
Clark, J.A., Wray, N.P., & Ashton, C.M. (2001). Living with treatment decisions: Regrets and quality of life among men treated for metastatic prostate cancer. Journal of Clinical Oncology, 19, 72-80.
22.
Cooperberg, M.R., Grossfeld, G.D., Lubeck, D.P., & Carroll, P.R. (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute, 95, 981-989.
23.
de Bakker, I.P., & Everaerd, W. (1996). Measurement of menopausal hot flushes: Validation and cross-validation. Maturitas, 25(2), 87-98.
24.
DMT 123. (2006). Retrieved December 12, 2006, from http://www.dmt123.com/other-health/1833-2-dmt123.html
25.
Dodd, M.J., Cho, M.H., Cooper, B., Miaskowski, C., Lee, K.A., & Bank, K. (2005). Advancing our knowledge of symptom clusters. Journal of Supportive Oncology, 3(6Suppl.4), 30-31.
26.
Dodd, M.J., Miaskowski, C., & Lee, K.A. (2004). Occurrence of symptom clusters. Journal of the National Cancer Institute. Monograph, 32, 76-78.
27.
Dreicer, R. (2000). The evolving role of hormone therapy in advanced prostate cancer. Cleveland Clinic Journal of Medicine, 67, 720-722, 725-726.
28.
Eaton, A.C., & McGuire, N. (1983). Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet, 2(8363), 1336-1337.
29.
Empson, J.A., & Purdie, D.W. (1999). Effects of sex steroids on sleep. Annals of Medicine, 31, 141-145.
30.
Engstrom, C. (2005). Hot flash experience in men with prostate cancer: A concept analysis. Oncology Nursing Forum, 32, 1043-1048.
31.
Engstrom, C.A., Strohl, R.A., Rose, L., Lewandowski, L., & Stefanek, M.E. (1999). Sleep alterations in cancer patients. Cancer Nursing, 22, 143-148.
32.
Filshie, J., Bolton, T., Browne, D., & Ashley, S. (2005). Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients-Audit and treatment algorithm . Acupuncture in Medicine, 23, 171-180.
33.
Freedman, R.R. (1989). Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology, 26, 573-579.
34.
Freedman, R.R. (2000). Hot flashes revisited. Menopause , 7(1), 3-4.
35.
Freedman, R.R. (2001). Physiology of hot flashes. American Journal of Human Biology, 13, 453-464.
36.
Freedman, R.R. (2005). Hot flashes: Behavioral treatments, mechanisms, and relation to sleep. American Journal of Medicine, 118(12Suppl.2), 124-130.
37.
Freedman, R.R., & Roehrs, T.A. (2004). Lack of sleep disturbance from menopausal hot flashes. Fertility and Sterility, 82, 138-144.
38.
Frodin, T., Alund, G., & Varenhorst, E. (1985). Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate , 7, 203-208.
39.
Gerber, G.S., Zagaja, G.P., Ray, P.S., & Rukstalis, D.B. (2000). Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology, 55, 97-101.
40.
Green, H.J., Pakenham, K.I., Headley, B.C., Yaxley, J., Nicol, D.L., Mactaggart, P.N., et al. (2002). Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU International , 90, 427-432.
41.
Hammar, M., Frisk, J., Grimas, O., Hook, M., Spetz, A.C., & Wyon, Y. (1999). Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: A pilot study. Journal of Urology , 161, 853-856.
42.
Heinemann, K., & Saad, F. (2003). Sweating attacks: Key symptom in menopausal transition only for women? European Urology, 44, 583-587.
43.
Herr, H.W., & O'Sullivan, M. (2000). Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. Journal of Urology, 163, 1743-1746.
44.
Higano, C.S. (2003). Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology, 61(2Suppl.1), 32-38.
45.
Huggins, C., Stevens, R.E., & Hodges, C.V. (1941). Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery, 43, 209-223.
46.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., et al. (2006). Cancer statistics, 2006. CA: A Cancer Journal for Clinicians, 56(2), 106-130.
47.
Kouriefs, C., Georgiou, M., & Ravi, R. (2002). Hot flushes and prostate cancer: Pathogenesis and treatment. BJU International, 89, 379-383.
48.
Kronenberg, F. (1990). Hot flashes: Epidemiology and physiology. Annals of the New York Academy of Sciences, 592, 52-86; discussion 123-133.
49.
Langenstroer, P., Kramer, B., Cutting, B., Amling, C., Poultan, T., Lance, R., et al. (2005). Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. Journal of Urology, 174(2), 642-645.
50.
Loprinzi, C.L., Barton, D.L., Carpenter, L.A., Sloan, J.A., Novotny, P.J., Gettman, M.T., et al. (2004). Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clinic Proceedings, 79, 1247-1251.
51.
Loprinzi, C.L., Goldberg, R.M., O'Fallon, J.R., Quella, S.K., Miser, A.W., Mynderse, L.A., et al. (1994). Transdermal clonidine for ameliorating post-orchiectomy hot flashes. Journal of Urology, 151, 634-636.
52.
Loprinzi, C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, R.A., et al. (1994). Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine, 331, 347-352.
53.
Loprinzi, C.L., Pisansky, T.M., Fonseca, R., Sloan, J.A., Zahasky, K.M., Quella, S.K., et al. (1998). Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. Journal of Clinical Oncology, 16, 2377-2381.
54.
Lu, P.H., Masterman, D.A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., et al. (2006). Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men . Archives of Neurology, 63, 177-185.
55.
Matsumoto, A.M. (2002). Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 57(2), M76-M99.
56.
Miller, H., & Li, R. (2004). Measuring hot flashes: Summary of a National Institutes of Health workshop. Mayo Clinic Proceedings, 79, 777-781.
57.
Miller, J.I., & Ahmann, F.R. (1992). Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology, 40, 499-502.
58.
Moe, K.E. (2004). Hot flashes and sleep in women. Sleep Medicine Reviews, 8, 487-497.
59.
National Cancer Institute. (2005). Surveillance epidemiology and end results. Retrieved March 5, 2005, from http://seer.cancer.gov/publications/prostate/incidence.html
60.
National Institutes of Health. (2004). Assessing and improving measures of hot flashes-Meeting summary. Retrieved January 18, 2007, from http://nccam.nih.gov/health/hotflashes/hotflash_summ.htm
61.
National Institutes of Nursing Research. ( 2004). Research themes for the future. Retrieved July 20, 2004, from http://ninr.nih.gov/ninr/research/themes.doc
62.
Nishiyama, T., Kanazawa, S., Watanabe, R., Terunuma, M., & Takahashi, K. (2004). Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. International Journal of Urology, 11, 735-741.
63.
Oncology Nursing Society. (2006a). ONS research agenda: Talking points. Retrieved December 12, 2006, from http://www.ons.org/research/information/documents/pdfs/talking05.pdf
64.
Oncology Nursing Society. (2006b). Quality cancer care. Retrieved December 12, 2006, from http://www.ons.org/publications/positions/QualityCancerCare.shtml
65.
Penson, D.F., & Litwin, M.S. (2003). Quality of life after treatment for prostate cancer . Current Urology Reports, 4(3), 185-195.
66.
Penson, D.F., Litwin, M.S., & Aaronson, N.K. (2003). Health related quality of life in men with prostate cancer. Journal of Urology, 169, 1653-1661.
67.
Petrylak, D.P., Ankerst, D.P., Jiang, C.S., Tangen, C.M., Hussain, M.H., Lara, P.N., Jr., et al. (2006). Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute, 98, 516-521.
68.
Quella, S.K., Loprinzi, C.L., Sloan, J., Novotny, P., Perez, E.A., Burch, P.A., et al. (1999). Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Journal of Urology, 1, 98-102.
69.
Salminen, E.K., Portin, R.I., Koskinen, A., Helenius, H., & Nurmi, M. (2004). Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clinical Cancer Research, 10, 7575-7582.
70.
Sartor, O., & Eastham, J.A. (1999). Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. Southern Medical Journal, 92, 415-416.
71.
Sculpher, M., Bryan, S., Fry, P., de Winter, P., Payne, H., & Emberton, M. (2004). Patients' preferences for the management of non-metastatic prostate cancer: Discrete choice experiment. British Medical Journal, 328(7436), 382.
72.
Seidenfeld, J., Samson, D.J., Aronson, N., Albertson, P.C., Bayoumi, A.M., Bennett, C., et al. (1999). Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer . Evidence Report/Technology Assessment (Summary), 4, i-x, 1-246, 1241-236, passim.
73.
Spencer, B.A., Steinberg, M., Malin, J., Adams, J., & Litwin, M.S. (2003). Quality-of-care indicators for early-stage prostate cancer. Journal of Clinical Oncology, 21, 1928-1936.
74.
Spetz, A.C., Pettersson, B., Varenhorst, E., Theodorsson, E., Thorell, L.H., & Hammar, M. (2001). Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. Journal of Urology, 166, 1720-1723.
75.
Spetz, A.C., Zetterlund, E.L., Varenhorst, E., & Hammar, M. (2003). Incidence and management of hot flashes in prostate cancer. Journal of Supportive Oncology, 1, 263-266, 269-270, 272-263; discussion 267-268, 271-262.
76.
Stearns, V., Ullmer, L., Lopez, J.F., Smith, Y., Isaacs, C., & Hayes, D. (2002). Hot flushes. Lancet, 360(9348), 1851-1861.
77.
Suzuki, K., Kobayashi, M., & Tokue, A. (2003). [Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma]. Nippon Hinyokika Gakkai Zasshi, 94, 614-620.
78.
Taxel, P., Stevens, M.C., Trahiotis, M., Zimmerman, J., & Kaplan, R.F. (2004). The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. Journal of the American Geriatrics Society , 52, 269-273.
79.
Thompson, C.A., Shanafelt, T.D., & Loprinzi, C.L. (2003). Andropause: Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist, 8, 474-487.
80.
van Andel, G., & Kurth, K.H. (2003). The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. European Urology, 44, 209-214.
81.
van Andel, G., Kurth, K.H., & de Haes, J.C. (1997). Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life. Urology Research, 25(Suppl. 2), S79-S88.
82.
Vermeulen, A. (1993). The male climacterium. Annals of Medicine, 25, 531-534.
83.
Walsh, B., & Schiff, I. (1990). Vasomotor flushes. Annals of the New York Academy of Sciences, 592, 346-356; discussion 390-344.
84.
Yaffe, K., Edwards, E.R., Lui, L.Y., Zmuda, J.M., Ferrell, R.E., & Cauley, J.A. (2003). Androgen receptor CAG repeat polymorphism is associated with cognitive function in older men. Biological Psychiatry , 54, 943-946.
85.
Yaffe, K., Lui, L.Y., Zmuda, J., & Cauley, J. (2002). Sex hormones and cognitive function in older men . Journal of the American Geriatric Society, 50, 707-712.
